PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.22%
Revenue growth under 50% of 3088.T's 4.77%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
0.43%
Gross profit growth under 50% of 3088.T's 4.33%. Michael Burry would be concerned about a severe competitive disadvantage.
3.96%
EBIT growth below 50% of 3088.T's 19.21%. Michael Burry would suspect deeper competitive or cost structure issues.
4.58%
Operating income growth under 50% of 3088.T's 25.52%. Michael Burry would be concerned about deeper cost or sales issues.
3.45%
Net income growth under 50% of 3088.T's 30.08%. Michael Burry would suspect the firm is falling well behind a key competitor.
3.44%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
3.44%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3088.T is at 1.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 1.27%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
4.61%
OCF growth above 1.5x 3088.T's 0.71%. David Dodd would confirm a clear edge in underlying cash generation.
4.61%
FCF growth above 1.5x 3088.T's 0.71%. David Dodd would verify if the firm’s strategic investments yield superior returns.
24.33%
10Y revenue/share CAGR under 50% of 3088.T's 109.45%. Michael Burry would suspect a lasting competitive disadvantage.
44.56%
5Y revenue/share CAGR at 50-75% of 3088.T's 71.36%. Martin Whitman would worry about a lagging mid-term growth trajectory.
20.69%
3Y revenue/share CAGR under 50% of 3088.T's 69.05%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.06%
Below 50% of 3088.T's 247.97%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
21.77%
Below 50% of 3088.T's 102.51%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-8.85%
Negative 3Y CAGR while 3088.T is 128.47%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
138.51%
Below 50% of 3088.T's 294.10%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
97.30%
5Y equity/share CAGR at 50-75% of 3088.T's 138.34%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
46.99%
Below 50% of 3088.T's 113.24%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
88.89%
Dividend/share CAGR of 88.89% while 3088.T is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
No Data
No Data available this quarter, please select a different quarter.
-2.02%
Firm’s AR is declining while 3088.T shows 23.97%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.88%
Inventory is declining while 3088.T stands at 3.88%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.52%
Negative asset growth while 3088.T invests at 2.23%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.65%
BV/share growth above 1.5x 3088.T's 0.55%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
73.31%
We have some new debt while 3088.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.